Detalhe da pesquisa
1.
Sensitizing protective tumor microenvironments to antibody-mediated therapy.
Cell
; 156(3): 590-602, 2014 Jan 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-24485462
2.
Acalabrutinib, venetoclax and obinutuzumab in relapsed CLL: Final efficacy and ctDNA analysis of the CLL2-BAAG trial.
Blood
; 2024 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38620072
3.
Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut.
Blood
; 142(11): 961-972, 2023 09 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37363867
4.
The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLL.
Blood
; 141(12): 1425-1441, 2023 03 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-36179280
5.
High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations.
Blood
; 142(5): 446-459, 2023 08 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37172204
6.
The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia.
Blood
; 139(2): 177-187, 2022 01 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-34758069
7.
General condition and comorbidity of long-term survivors of adult acute lymphoblastic leukemia.
Haematologica
; 108(7): 1758-1767, 2023 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36779593
8.
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.
N Engl J Med
; 380(23): 2225-2236, 2019 Jun 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31166681
9.
Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax.
Blood
; 135(26): 2402-2412, 2020 06 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-32206772
10.
Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicenter, open-label phase-II trial.
Haematologica
; 106(2): 543-554, 2021 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32107341
11.
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 21(9): 1188-1200, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32888452
12.
Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis.
Cochrane Database Syst Rev
; 7: CD012022, 2020 07 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-32735048
13.
Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2-BCG): Final analysis of a multicenter, open-label phase-II-trial.
Am J Hematol
; 99(6): 1192-1195, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38578022
14.
Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial.
Lancet Oncol
; 19(9): 1215-1228, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30115596
15.
Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy.
Blood
; 128(3): 395-404, 2016 07 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-27226433
16.
Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial.
Blood
; 127(2): 208-15, 2016 Jan 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-26486789
17.
Frontline therapy of acute promyelocytic leukemia: Randomized comparison of ATRA and intensified chemotherapy versus ATRA and anthracyclines.
Eur J Haematol
; 100(2): 154-162, 2018 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-29114972
18.
CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia.
Future Oncol
; 14(6): 499-513, 2018 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-29465308
19.
Effects of all-trans retinoic acid (ATRA) in addition to chemotherapy for adults with acute myeloid leukaemia (AML) (non-acute promyelocytic leukaemia (non-APL)).
Cochrane Database Syst Rev
; 8: CD011960, 2018 08 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30080246
20.
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.
N Engl J Med
; 370(12): 1101-10, 2014 Mar 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-24401022